CLAIMS

[Claim 1]

A dry-coated tablet comprising:

an inner core containing, as active ingredients, (a) tegafur, (b) gimeracil, and (c) oteracil potassium, and

an outer shell.

[Claim 2]

The dry-coated tablet according to claim 1, containing (a) tegafur, (b) gimeracil, and (c) oteracil potassium at a molar ratio of 1:0.4:1.

[Claim 3]

The dry-coated tablet according to claim 1 or 2, wherein the active ingredients consisting of (a) tegafur, (b) gimeracil, and (c) oteracil potassium account for 50 mass% to 100 mass% of components of the inner core.

[Claim 4]

The dry-coated tablet according to any one of claims 1 to 3, wherein the active ingredients consisting of (a) tegafur, (b) gimeracil, and (c) oteracil potassium account for 70 mass% to 99 mass% of components of the inner core.

[Claim 5]

The dry-coated tablet according to any one of claims 1 to 4, wherein the total content of the active ingredients (a) to (c) accounts for 10 to 60 mass% of the dry-coated tablet.

[Claim 6]

The dry-coated tablet according to any one of claims 1 to 5, wherein the outer shell contains one, two, or three compounds among lactose, crystalline cellulose, and hydroxypropyl cellulose.

[Claim 7]

The dry-coated tablet according to claim 6, wherein the outer shell contains one or two compounds among lactose and crystalline cellulose.

[Claim 8]

The dry-coated tablet according to claim 7, wherein the outer shell contains lactose and crystalline cellulose.

[Claim 9]

The dry-coated tablet according to claim 6, 7, or 8, wherein the outer shell further contains a disintegrant.

[Claim 10]

The dry-coated tablet according to claim 9, wherein the disintegrant is selected from the group consisting of crospovidone, carmellose, corn starch, low-substituted hydroxypropyl cellulose, and partially pregelatinized starch.

[Claim 11]

The dry-coated tablet according to claim 10, wherein the disintegrant is crospovidone and/or partially pregelatinized starch.

[Claim 12]

The dry-coated tablet according to any one of claims 1 to 11, wherein the outer shell contains 30 to 65 mass% lactose.

[Claim 13]

The dry-coated tablet according to any one of claims 1 to 12, wherein the outer shell contains 30 to 50 mass% crystalline cellulose.

[Claim 14]

The dry-coated tablet according to any one of claims 1

to 13, wherein the outer shell contains 2.5 to 15 mass% crospovidone.

[Claim 15]

The dry-coated tablet according to any one of claims 1 to 14, wherein the outer shell contains 2 to 7.5 mass% partially pregelatinized starch.

[Claim 16]

The dry-coated tablet according to any one of claims 1 to 15, wherein the dry-coated tablet has an outer shell that causes the dry-coated tablet to have a friability (accumulative number of rotations: 100 rotations) of not higher than 0.3%, and the disintegration time of the dry-coated tablet determined by the Disintegration Test described in the General Tests, Processes and Apparatus section of the Japanese Pharmacopoeia is not more than 120 seconds.

[Claim 17]

The dry-coated tablet according to any one of claims 1 to 16, wherein the dry-coated tablet has an outer shell that causes the dry-coated tablet to have a friability (accumulative number of rotations: 100 rotations) of not higher than 0.2%, and that substantially does not become cracked or chipped after a drop test from a height of 1 m, and the disintegration time of the dry-coated tablet determined by the Disintegration Test described in the General Tests, Processes and Apparatus section of the Japanese Pharmacopoeia is not more than 95 seconds.

CLAIMS

[Claim 1]

A dry-coated tablet comprising:

an inner core containing, as active ingredients, (a) tegafur, (b) gimeracil, and (c) oteracil potassium, and

an outer shell

wherein the dry-coated tablet is an orally disintegrating tablet,

the active ingredients consisting of (a) tegafur, (b) gimeracil, and (c) oteracil potassium account for 70 mass% to 99 mass% of components of the inner core, and

the outer shell contains 30 to 50 mass% crystalline cellulose.

[Claim 2]

The dry-coated tablet according to claim 1, containing (a) tegafur, (b) gimeracil, and (c) oteracil potassium at a molar ratio of 1:0.4:1.

[Claim 3]

The dry-coated tablet according to claim 1 or 2, wherein the total content of the active ingredients (a) to (c) accounts for 10 to 60 mass% of the dry-coated tablet.

[Claim 4]

The dry-coated tablet according to any one of claims 1 to 3, wherein the outer shell contains one, or two compounds among lactose and hydroxypropyl cellulose.

[Claim 5]

The dry-coated tablet according to claim 4, wherein the outer shell contains lactose .

[Claim 6]

The dry-coated tablet according to claim 4 or 5, wherein the outer shell further contains a disintegrant.

[Claim 7]

The dry-coated tablet according to claim 6, wherein the disintegrant is selected from the group consisting of crospovidone, carmellose, corn starch, low-substituted hydroxypropyl cellulose, and partially pregelatinized starch.

[Claim 8]

The dry-coated tablet according to claim 7, wherein the disintegrant is crospovidone and/or partially pregelatinized starch.

[Claim 9]

The dry-coated tablet according to any one of claims 1 to 8, wherein the outer shell contains 30 to 65 mass% lactose.

[Claim 10]

The dry-coated tablet according to any one of claims 1 to 9, wherein the outer shell contains 2.5 to 15 mass% crospovidone.

[Claim 11]

The dry-coated tablet according to any one of claims 1 to 10, wherein the outer shell contains 2 to 7.5 mass% partially pregelatinized starch.

[Claim 12]

The dry-coated tablet according to any one of claims 1 to 11, wherein the dry-coated tablet has an outer shell that causes the dry-coated tablet to have a friability (accumulative number of rotations: 100 rotations) of not higher than 0.3%, and the disintegration time of the dry-coated tablet determined by the Disintegration Test described in the General Tests, Processes and Apparatus section of the Japanese Pharmacopoeia is not more than 120 seconds.

[Claim 13]

The dry-coated tablet according to any one of claims 1 to 12, wherein the dry-coated tablet has an outer shell that causes the dry-coated tablet to have a friability (accumulative number of rotations: 100 rotations) of not higher than 0.2%, and that substantially does not become cracked or chipped after a drop test from a height of 1 m, and the disintegration time of the dry-coated tablet determined by the Disintegration Test described in the General Tests, Processes and Apparatus section of the Japanese Pharmacopoeia is not more than 95 seconds.